Kluge Martin, Leder Annekatrin, Hillebrandt Karl H, Struecker Benjamin, Geisel Dominik, Denecke Timm, Major Rebeka D, Reutzel-Selke Anja, Tang Peter, Lippert Steffen, Schmidt Christian, Pratschke Johann, Sauer Igor M, Raschzok Nathanael
1 Department of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Experimental Surgery and Regenerative Medicine, Charité - Universitätsmedizin Berlin , Berlin, Germany .
2 Department of Diagnostic and Interventional Radiology, Charité - Universitätsmedizin Berlin , Campus Virchow-Klinikum, Berlin, Germany .
Tissue Eng Part C Methods. 2017 Jul;23(7):412-421. doi: 10.1089/ten.TEC.2017.0118. Epub 2017 Jun 23.
Labeling using iron oxide particles enables cell tracking through magnetic resonance imaging (MRI). However, the magnetic field can affect the particle-labeled cells. Here, we investigated the effects of a clinical MRI system on primary human hepatocytes labeled using micrometer-sized iron oxide particles (MPIOs).
HuH7 tumor cells were incubated with increasing concentrations of biocompatible, silica-based, micrometer-sized iron oxide-containing particles (sMPIOs; 40-160 particles/cell). Primary human hepatocytes were incubated with 100 sMPIOs/cell. The particle-labeled cells and the native cells were imaged using a clinical 3.0 T MRI system, whereas the control groups of the labeled and unlabeled cells were kept at room temperature without exposure to a magnetic field. Viability, formation of reactive oxygen species (ROS), aspartate aminotransferase leakage, and urea and albumin synthesis were assessed for a culture period of 5 days.
The dose finding study showed no adverse effects of the sMPIOs labeling on HuH7 cells. MRI had no adverse effects on the morphology of the sMPIO-labeled primary human hepatocytes. Imaging using the T1- and T2-weighted sequences did not affect the viability, transaminase leakage, formation of ROS, or metabolic activity of the sMPIO-labeled cells or the unlabeled, primary human hepatocytes.
sMPIOs did not induce adverse effects on the labeled cells under the conditions of the magnetic field of a clinical MRI system.
使用氧化铁颗粒进行标记可通过磁共振成像（MRI）实现细胞追踪。然而，磁场会影响颗粒标记的细胞。在此，我们研究了临床MRI系统对使用微米级氧化铁颗粒（MPIOs）标记的原代人肝细胞的影响。
将HuH7肿瘤细胞与浓度不断增加的生物相容性、基于二氧化硅的微米级含氧化铁颗粒（sMPIOs；40 - 160个颗粒/细胞）一起孵育。将原代人肝细胞与100个sMPIOs/细胞一起孵育。使用临床3.0 T MRI系统对颗粒标记的细胞和天然细胞进行成像，而标记和未标记细胞的对照组则保持在室温下，不暴露于磁场。在5天的培养期内评估细胞活力、活性氧（ROS）的形成、天冬氨酸转氨酶泄漏以及尿素和白蛋白的合成。
剂量探索研究表明sMPIOs标记对HuH7细胞没有不良影响。MRI对sMPIOs标记的原代人肝细胞的形态没有不良影响。使用T1加权和T2加权序列成像不会影响sMPIOs标记细胞或未标记的原代人肝细胞的活力、转氨酶泄漏、ROS形成或代谢活性。
在临床MRI系统的磁场条件下，sMPIOs对标记细胞未产生不良影响。
